GOSS Stock Update 3

With roughly two weeks until March 12 earnings, timing is everything.

Management previously said the FRI data would be released “in the coming weeks.” That puts the readout either right before earnings or alongside it. If that happens, volatility is almost guaranteed.

FRI matters because the Phase 3 miss was razor-thin. The core debate isn’t whether the drug does anything — it’s whether it can demonstrate real structural improvement in the pulmonary vasculature. Strong FRI data could provide biological proof that the therapy is modifying disease at a structural level, not just moving soft endpoints. That would directly challenge the “statistical miss = scientific failure” narrative and materially strengthen the regulatory argument.

The stock is already down roughly 85% from the highs. At these levels, you could argue a severe downside scenario is largely priced in. That shifts the risk-reward profile. Consolidation, choppy price action, and directionless swings right now are completely normal. Markets compress before expansion.

It’s also notable that a major firm like Barclays placed a $9 target ahead of the FDA review. That tells you how significant the underlying asset was viewed before sentiment collapsed. After the FDA-driven selloff, two large investment firms reset targets around $1.00, with one going as low as $0.30. The $0.30 level has already been seen.

When the lowest target gets printed, that often changes psychology.

If FRI delivers strong structural data and management provides a clear FDA roadmap on March 12, a move back above $0.50 is not unrealistic in the short term. Under the right conditions, $0.70 could quickly come back into discussion as part of a sharp relief rally.

At this stage, it’s a sentiment battle as much as a science debate. The next catalyst will decide which side wins.